Picture loading failed.

Anti-IL17A therapeutic antibody (Pre-made Netakimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federation, registration certificate number ЛП-005439 from 04.04. 2019.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-374-1mg 1mg 3090
GMP-Bios-ab-374-10mg 10mg 21890
GMP-Bios-ab-374-100mg 100mg 148000
GMP-Bios-ab-374-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL17A therapeutic antibody (Pre-made Netakimab biosimilar,Whole mAb)
INN Name Netakimab
TargetIL17A
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesCJSC Biocad
Conditions ApprovedPlaque psoriasis
Conditions ActiveAnkylosing spondylitis;Psoriatic Arthritis;Primary biliary cirrhosis
Conditions Discontinuedna
Development Techna